GlaxoSmithKline woos Pfizer medicinal sciences chief Tony Wood to high-level R&D job

GlaxoSmithKline has been actively recruiting a slate of new execs for the company as Emma Walmsley settles into her new job as CEO.

The latest pick up: Tony Wood, Pfizer’s senior vice president of medicinal sciences, has been wooed over to take a key R&D posting at the UK pharma giant. And the move includes a shift in assignments tied to a new effort at GSK involving the use of artificial intelligence in drug development.

The news, first reported by FierceBiotech, was confirmed to me this morning.

From GSK:

Tony Wood has been appointed Senior Vice President, Platform Technology and Science, Pharma R&D at GSK and will assume his position in October.  In this role he will be responsible for delivering the critical end-to-end scientific and technical platform that supports the discovery and development of our medicines. This appointment reflects our ongoing commitment to the successful delivery of our deep mid-stage pipeline and enhancing our R&D capabilities, particularly in areas such as computational sciences.

The spokesperson adds that John Baldoni, who previously led this effort, is moving to head up a new team focused on “enhancing drug discovery through the use of in silico technology — including artificial intelligence, machine learning and deep learning.”

The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription